Drug Interactions Between Ingrezza (Valbenazine) and Zoloft (Sertraline)
Ingrezza and Zoloft can be used together, but the Ingrezza dose should be reduced to 40 mg once daily when combined with sertraline due to a CYP2D6-mediated interaction.
CYP Enzyme Interaction Profile
Sertraline's CYP Effects
Sertraline has moderate inhibitory effects on CYP2D6 1. While sertraline is metabolized by multiple pathways including CYP2B6 (primary), CYP2C19, CYP2C9, CYP3A4, and CYP2D6 2, it acts as an inhibitor of CYP2D6 when co-administered with other medications. Research demonstrates that sertraline at therapeutic doses (mean 94 mg/day) produces modest but significant CYP2D6 inhibition 3.
Importantly, sertraline also exhibits time-dependent inhibition of CYP3A4 through metabolic intermediate complex formation 4, though clinical studies show this does not significantly affect CYP3A4 substrates in vivo at standard doses 5.
Ingrezza's CYP Metabolism
Valbenazine (Ingrezza) is primarily metabolized by CYP3A4 to form its active metabolite (+)-α-HTBZ, which is then further metabolized by CYP2D6 6. The FDA label explicitly states that strong CYP2D6 inhibitors increase exposure to valbenazine's active metabolite, necessitating dose reduction 6.
Specific Dosing Recommendation
When combining Ingrezza with Zoloft:
- Reduce Ingrezza dose to 40 mg once daily 6
- This applies whether using Ingrezza capsules or Ingrezza Sprinkle formulation
- The dose reduction is necessary because sertraline's CYP2D6 inhibition increases exposure to valbenazine's active metabolite (+)-α-HTBZ, which has a half-life of approximately 22 hours 7
Additional Safety Considerations
Serotonin Syndrome Risk
While both medications affect serotonergic pathways, the primary concern is not a direct serotonin syndrome interaction. However, clinicians should remain vigilant for serotonin syndrome symptoms when combining any serotonergic medications 1:
- Mental status changes (confusion, agitation)
- Neuromuscular hyperactivity (tremors, clonus, hyperreflexia)
- Autonomic hyperactivity (hypertension, tachycardia, diaphoresis)
QTc Prolongation
Sertraline may interact with drugs that prolong QTc interval 1, 8. While Ingrezza is not specifically listed as a QTc-prolonging agent in the provided evidence, monitor for additive cardiac effects if the patient has other risk factors.
MAOI Contraindication
Avoid combining Ingrezza with MAOIs or within 14 days of MAOI discontinuation 6. This is separate from the sertraline interaction but important for overall medication management.
Clinical Monitoring
When initiating this combination:
- Start with the reduced Ingrezza dose (40 mg daily) from the outset if sertraline is already on board
- Monitor for increased adverse effects related to VMAT2 inhibition (somnolence, akathisia, fatigue)
- Assess for adequate therapeutic response, as the reduced dose may affect efficacy
- Watch for exposure-related adverse reactions including sedation and extrapyramidal symptoms 6
The interaction is pharmacokinetic via CYP2D6 inhibition, not a contraindication, and is manageable with appropriate dose adjustment.